Curis, Inc. is a drug discovery and development company committed to leveraging signaling pathway drug technologies in seeking to create new medicines, primarily for cancer. The Company’s product candidates include Hedgehog Pathway Inhibitor and other targeted cancer programs. The Company’s targeted cancer programs primarily consist of several drug programs through, which it had produced single small molecules that target one or more signaling pathways.